Health Canada has initiated a review of the application for approval of healthcare company Swedish Orphan Biovitrum’s (Sobi) Orfadin (nitisinone) capsules to treat hereditary tyrosinaemia type-I (HT-1).

HT-1 is a rare but progressive genetic disease that causes liver and kidney problems in infants and children and can be fatal if left untreated.

People affected with HT-1 face problems in breaking down an amino acid called tyrosine, which results in the formation of toxic by-products that accumulate in the body, causing liver, renal and neurological issues.

Orfadin (nitisinone) helps block the breakdown of tyrosine, thereby reducing the amount of toxic tyrosine by-products in the person’s body.

"If approved, it will be a major step in ensuring that HT-1 patients throughout Canada could have sustainable access to Orfadin treatment going forward."

Sobi core poducts global medical affairs head Michael Yeh said: “We are very pleased that the review process for Orfadin capsules in Canada has started.

“Canada and Quebec is home to 10% of the world’s HT-1 population and has been a priority for Sobi since we took direct responsibility for Orfadin in the region.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“If approved, it will be a major step in ensuring that HT-1 patients throughout Canada could have sustainable access to Orfadin treatment going forward.”

Orfadin (nitisinone) is approved in the US and Europe to treat patients with HT-1, along with dietary restriction of tyrosine and phenylalanine.

Once approved in Canada, the range of dosing alternatives, 2mg, 5mg, 10mg, and 20mg capsules, will be able to offer personalised treatment for HT-1 patients.